Dupont Capital Management Corp lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 11.5% during the 2nd quarter, Holdings Channel reports. The fund owned 229,389 shares of the company’s stock after selling 29,815 shares during the period. Johnson & Johnson makes up approximately 0.7% of Dupont Capital Management Corp’s holdings, making the stock its 17th biggest holding. Dupont Capital Management Corp’s holdings in Johnson & Johnson were worth $27,834,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in JNJ. BlackRock Inc. grew its position in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after buying an additional 7,853,141 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Johnson & Johnson by 1.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after buying an additional 541,338 shares in the last quarter. Fisher Asset Management LLC grew its position in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after buying an additional 478,982 shares in the last quarter. Boston Partners grew its position in shares of Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after buying an additional 5,207,124 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Johnson & Johnson by 9.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock worth $967,793,000 after buying an additional 654,350 shares in the last quarter. 66.60% of the stock is currently owned by institutional investors.
Johnson & Johnson stock opened at $142.20 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The stock has a market capitalization of $377.43 billion, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 2.20 and a beta of 0.58.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the business posted $1.90 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be paid a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Company insiders own 0.22% of the company’s stock.
A number of equities research analysts recently weighed in on JNJ shares. Raymond James upped their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Credit Suisse Group upped their price objective on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Goldman Sachs Group upgraded Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Citigroup upped their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $142.54.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Dupont Capital Management Corp” was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://macondaily.com/2018/11/06/johnson-johnson-jnj-shares-sold-by-dupont-capital-management-corp.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.